|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of mosapride citrate with polyethylene glycol solution for colonoscopy preparation显示文摘AIM:To evaluate the efficacy and safety of adjunctive mosapride citrate for bowel preparation before colonoscopy. METHODS:We conducted a randomized,double-blind, placebo-controlled study with mosapride in addition to polyethylene glycol(PEG)-electrolyte solution.Of 250 patients undergoing colonoscopy,124 were randomized to receive 2 L PEG plus 15 mg of mosapride citrate (mosapride group),and 126 received 2 L PEG plus placebo(placebo group).Patients completed a questionnaire reporting the acceptability and tolerability of the bowel preparation process.The efficacy of bowel preparation was assessed by colonoscopists using a 5-point scale based on Aronchick's criteria.The primary end point was optimal bowel preparation rates(scores of excellent/good/fair vs poor/inadequate). RESULTS:A total of 249 patients were included in the analysis.In the mosapride group,optimal bowel preparation rates were significantly higher in the left colon compared with the placebo group(78.2%vs 65.6%,P<0.05),but not in the right colon(76.5%vs 66.4%,P=0.08).After excluding patients with severe constipation,there was a significant difference in bowel preparation in both the left and right colon(82.4%vs 66.7%,80.8%vs 67.5%,P<0.05,P<0.01).The incidence of adverse events was similar in both groups. Among the subgroup who had previous colonoscopy experience,a significantly higher number of patients in the mosapride group felt that the current preparation was easier compared with patients in the placebo group(34/72 patients vs 24/74 patients,P<0.05). CONCLUSION:Mosapride citrate may be an effective and safe adjunct to PEG-electrolyte solution that leads to improved quality of bowel preparation,especially in patients without severe constipation. | Masahiro Tajika Yasumasa Niwa Vikram Bhatia Hiroki Kawai Shinya Kondo Akira Sawaki Nobumasa Mizuno Kazuo Hara Susumu Hijioka Kazuya Matsumoto Yuji Kobayashi Akira Saeki Asana Akabane Koji Komori Kenji Yamao | 2012 | World Journal of Gastroenterology2012，18，20： | 21 |
| 2 | Can mosapride citrate reduce the volume of lavage solution for colonoscopy preparation?显示文摘AIM:To evaluate the possibility of reducing the volume of polyethylene glycol(PEG)-electrolyte solution using adjunctive mosapride citrate for colonoscopy preparation. METHODS:This was a single-center,prospective, randomized,investigator-blinded,non-inferiority study involving 252 patients of both sexes,aged from 20 to 80 years,scheduled for screening or diagnostic colonoscopy in our department.A total of 126 patients was randomized to receive 1.5 L PEG-electrolyte solution plus 15 mg of mosapride(1.5 L group),and 126 received 2 L PEG-electrolyte solution plus 15 mg of mosapride(2 L group).Patients completed a questionnaire on the acceptability and tolerability of the bowel preparation process.The efficacy of bowel preparation was assessed using a 5-point scale based on the Aronchick scale.The primary end point was adequate bowel preparation rates(score of excellent/good/fair) vs(poor/inadequate).Acceptability and tolerability,as well as disease detection,were secondary end points. RESULTS:A total of 244 patients was included in the analysis.There were no significant differences between the 2 L and 1.5 L groups in age,sex,body mass index, number of previous colonoscopies,and the preparation method used previously.The adequate bowel preparation rates were 88.5%in the 2 L group and 82.8%in the 1.5 L group[95%lower confidence limit(LCL)for the difference=-14.5%,non-inferiority P=0.019]in the right colon.In the left colon,the adequate bowel preparation rates were 89.3%in the 2 L group and 81.1%in the 1.5 L group(95%LCL=-17.0%,non-inferiority P=0.066).Compliance,defined as complete (100%)intake of the PEG solution,was significantly higher in the 1.5 L group than in the 2 L group(96.8% vs 85.7%,P=0.002).The proportion of abdominal distension(none/mild/moderate/severe)was significantly lower in the 1.5 L group than in the 2 L group (36/65/22/3 vs 58/48/18/2,P=0.040).Within the subgroup who had undergone colonoscopy previously, a significantly higher number of patients in the 1.5 L group than in the 2 L group felt that the current preparation was easier than the previous one(54.1%vs 28.0%,P=0.001).The disease detection rate was not significantly different between the two groups. CONCLUSION:Although the 1.5 L group had better acceptability and tolerability,15 mg of mosapride may be insufficient to compensate for a 0.5-L reduction of PEG solution. | Masahiro Tajika Yasumasa Niwa Vikram Bhatia Shinya Kondo Tsutomu Tanaka Nobumasa Mizuno Kazuo Hara Susumu Hijioka Hiroshi Imaoka Koji Komori Kenji Yamao | 2013 | World Journal of Gastroenterology2013，19，5： | 8 |
| 3 | Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma显示文摘BACKGROUND Recent advances in endoscopic technology,especially magnifying endoscopy with narrow band imaging(ME-NBI)enable us to detect superficial esophageal squamous cell carcinoma(ESCC),but determining the appropriate method of resection,endoscopic resection(ER)vs surgical resection,is often challenging.Recently,several studies have reported that 18F-fluorodeoxyglucose positron emission tomography(FDG-PET)is a useful indicator for decision-making regarding treatment for superficial ESCC.Although,there are not enough reports on association between FDG-PET uptake and clinicopathological characteristics of superficial ESCC.And,there are not enough reports on evaluating the usefulness of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC.This study evaluated clinical relevance of FDG-PET and ME-NBI in decision-making regarding the treatment strategy for ESCC.AIM To investigate the association between FDG uptake and the clinicopathological characteristics of superficial ESCC and its usefulness of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC.METHODS A database of all patients with superficial ESCC who had undergone both MENBI and FDG-PET for pre-treatment staging at Aichi Cancer Center Hospital between January 2008 and November 2018 was retrospectively analyzed.FDG uptake was defined positive or negative whether the primary lesion was visualized or could be distinguished from the background,or not.The invasion depth of ESCC was classified according to the Japan Esophageal Society.Primary endpoint is to evaluate the association between FDG uptake and clinicopathological characteristics of superficial ESCC.Secondary endpoint is to investigate the efficacy of combination of FDG-PET and ME-NBI for determining the treatment strategy for superficial ESCC.RESULTS A total of 82 lesions in 82 patients were included.FDG-PET showed positive uptake in 29(35.4%)lesions.Univariate analysis showed that uptake of FDG-PET had significant correlations with circumferential extension(P=0.014),pathological depth of tumor invasion(P<0.001),infiltrative growth pattern(P<0.001),histological grade(P=0.002),vascular invasion(P=0.001),and lymphatic invasion(P<0.001).On multivariate analysis,only depth of tumor invasion was independently correlated with FDG-PET/computed tomography visibility(P=0.018).The sensitivity,specificity,positive predictive value(PPV),negative predictive value(NPV),and accuracy of Type B2 in ME-NBI for the invasion depth of T1a muscularis mucosae and T1b upper submucosal layer were 68.4%/79.4%/50.0%/89.3%/76.8%,respectively,and those of Type B3 for the depth of T1b middle and deeper submucosal layers(SM2 and SM3)were 46.7%/100%/100%/89.3%/90.2%,respectively.On the other hand,those of FDGPET for SM2 and SM3 were 93.3%/77.6%/48.2%/98.1%/80.5%,respectively,whereas,if the combination of positive FDG uptake and type B2 and B3 was defined as an indicator for radical esophagectomy or definitive chemoradiotherapy,the sensitivity,specificity,PPV,NPV,and accuracy were 78.3%/91.5%/78.3%/91.5%/87.8%,respectively.CONCLUSION FDG uptake was correlated with the invasion depth of superficial ESCC.Combined use of FDG-PET and ME-NBI,especially with the microvascular findings of Type B2 and B3,is useful to determine whether ER is indicated for the lesion. | Kazuhiro Toriyama Masahiro Tajika Tsutomu Tanaka Makoto Ishihara Yutaka Hirayama Sachiyo Onishi Nobumasa Mizuno Takamichi Kuwahara Nozomi Okuno Shinpei Matsumoto Eiichi Sasaki Tetsuya Abe Yasushi Yatabe Kazuo Hara Keitaro Matsuo Tsuneo Tamaki Yasumasa Niwa | 2019 | World Journal of Gastroenterology2019，25，46： | 7 |
| 4 | Prospective clinical study of endoscopic ultrasound-guided choledochoduodenostomy with direct metallic stent placement using a forward-viewing echoendoscope显示文摘 | K. Hara K. Yamao S. Hijioka N. Mizuno H. Imaoka M. Tajika S. Kondo T. Tanaka S. Haba O. Takeshi Y. Nagashio T. Obayashi A. Shinagawa V. Bhatia Y. Shimizu H. Goto Y. Niwa | 2013 | Endoscopy2013，，05： | 6 |
| 5 | endoscopic ultrasonography-guided biliary drainage:Who,when,which,and how?显示文摘Both endoscopic ultrasonography(EUS)-guided choledochoduodenostomy( EUS- CDS) and EUS-guided hepaticogastrostomy(EUS-HGS) are relatively well established as alternatives to percutaneous transhepatic biliary drainage(PTBD). Both EUSCDS and EUS-HGS have high technical and clinical success rates(more than 90%) in high-volume centers. Complications for both procedures remain high at 10%-30%. Procedures performed by endoscopists who have done fewer than 20 cases sometimes result in severe or fatal complications. When learning EUSguided biliary drainage(EUS-BD), we recommend a mentor's supervision during at least the first 20 cases. For inoperable malignant lower biliary obstruction, a skillful endoscopist should perform EUS-BD before EUS-guided rendezvous technique(EUS-RV) and PTBD. We should be select EUS-BD for patients having altered anatomy from malignant tumors before balloon-enteroscope-assisted endoscopic retrograde cholangiopancreatography, EUS-RV, and PTBD. If both EUS-CDS and EUS-HGS are available, we should select EUS-CDS, according to published data. EUSBD will potentially become a first-line biliary drainage procedure in the near future. | Kazuo Hara Kenji Yamao Nobumasa Mizuno Susumu Hijioka Hiroshi Imaoka Masahiro Tajika Tutomu Tanaka Makoto Ishihara Nozomi Okuno Nobuhiro Hieda Tukasa Yoshida Yasumasa Niwa | 2016 | World Journal of Gastroenterology2016，22，3： | 4 |
| 6 | Prognostic value of K - ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer显示文摘 | Takeshi Ogura Kenji Yamao Kazuo Hara Nobumasa Mizuno Susumu Hijioka Hiroshi Imaoka Akira Sawaki Yasumasa Niwa Masahiro Tajika Shinya Kondo Tsutomu Tanaka Yasuhiro Shimizu Vikram Bhatia Kazuhide Higuchi Waki Hosoda Yasushi Yatabe | 2013 | Journal of Gastroenterology2013，，5： | 4 |
| 7 | Risk of ileal pouch neoplasms in patients with familial adenomatous polyposis显示文摘Restorative proctocolectomy is the most common surgical option for patients with familial adenomatous polyposis(FAP). However,adenomas may develop in the ileal pouch mucosa over time,and even carcinoma in the pouch has been reported. We therefore reviewed the prevalence,nature,and treatment of adenomas and carcinoma that develop after proctocolectomy in the ileal pouch mucosa in patients with FAP. In 25 reports that were reviewed,the incidence of adenomas in the ileal pouch varied from 6.7% to 73.9%. Several potential factors that favor the development of pouch polyposis have been investigated,but many remain controversial. Nevertheless,it seems certain that the age of the pouch is important. The risk appears to be 7%to 16% after 5 years,35% to 42% after 10 years,and75% after 15 years. On the other hand,only 21 cases of ileal pouch carcinoma have been recorded in the literature to date. The diagnosis of pouch carcinoma was made between 3 to 20 years(median,10 years) after pouch construction. Although the risk of malignant transformation in ileal pouches is probably low,it is not negligible,and the long-term risk cannot presently be well quantified. Regular endoscopic surveillance,especially using chromoendoscopy,is recommended. | Masahiro Tajika Yasumasa Niwa Vikram Bhatia Tsutomu Tanaka Makoto Ishihara Kenji Yamao | 2013 | World Journal of Gastroenterology2013，19，40： | 4 |
| 8 | Prognostic value of energy metabolism in patients with viral liver cirrhosis显示文摘 | Masahiro Tajika Masahiko Kato Hiromi Mohri Yoshiyuki Miwa Tomohiro Kato Hiroo Ohnishi Hisataka Moriwaki | 2002 | Nutrition2002，，3： | 2 |
| 9 | Interventional endoscopic ultrasonography for pancreatic cancer显示文摘Endoscopic ultrasonography(EUS)represents the combination of endoscopy and intraluminal ultrasonography.This allows use of a high-frequency transducer(5-20 MHz)that,due to the short distance to the target lesion,provides ultrasonographic images of higher resolution than those obtained from other imaging modalities,including multiple-detector-row-computed tomography,magnetic resonance imaging,and positron emission tomography.EUS is now a widely accepted modality for diagnosing pancreatic diseases.However,the most important limitation of EUS has been the lack of specificity in differentiating between benign and malignant changes.In 1992,EUS-guided fine needle aspiration(FNA)of lesions in the pancreas head was introduced into clinical practice,using a curved linear-array echoendoscope.Since then,EUS has evolved from EUS imaging to EUSFNA and wider applications.Interventional EUS for pancreatic cancer includes EUS-FNA,EUS-guided fine needle injection,EUS-guided biliary drainage and anastomosis,EUS-guided celiac neurolysis,radiofrequency ablation,brachytherapy,and delivery of a growing number of anti-tumor agents.This review focuses on interventional EUS,including EUS-FNA and therapeutic EUS for pancreatic cancer. | Kazuo Hara Kenji Yamao Nobumasa Mizuno Susumu Hijioka Akira Sawaki Masahiro Tajika Hiroki Kawai Shinya Kondo Yasuhiro Shimizu Yasumasa Niwa | 2011 | World Journal of Clinical Oncology2011，2，2： | 2 |
| 10 | Endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of gastrointestinal stromal tumors in the stomach显示文摘 | Kenji Okubo Kenji Yamao Tsuneya Nakamura Masahiro Tajika Akira Sawaki Kazuo Hara Hiroki Kawai Yoshitaka Yamamura Yoshinari Mochizuki Takashi Koshikawa Ken-ichi Inada | 2004 | Journal of Gastroenterology2004，，8： | 2 |
| 11 | Aquaporins in the digestive system显示文摘 | Toshiyuki Matsuzaki Yuki Tajika Abdushukur Ablimit Takeo Aoki Haruo Hagiwara Kuniaki Takata | 2004 | Medical Electron Microscopy2004，，2： | 2 |
| 12 | Aquaporins: a water channel family显示文摘 | Matsuzaki T Tajika Y Tserentsoodol N | 2002 | Anat Sci Int2002，77，： | 1 |
| 13 | Aquaporins: water channel proteins of the cell membrane显示文摘 | Kuniaki Takata Toshiyuki Matsuzaki Yuki Tajika | 2004 | Progress in Histochumistry and Cytochemistry2004，39，： | 1 |
| 14 | Calcium oxide as a solid base catalyst for transesterification of soybean oil and its application to biodiesel production显示文摘 | Kouzu M Kasuno T Tajika M | 2008 | Fuel2008，87，： | 1 |
| 15 | 1' - acetoxychavicol Acetate as an inhibitor of phagocytosis of macrophages显示文摘 | Watanabe N Kataoka T Tajika T | 1995 | Biosci Biotechnol Biochem1995，59，： | 1 |
| 16 | Aquaporins: water channel proteins of the cell membrane显示文摘 | Takata K Matsuzaki T Tajika Y | 2004 | Progr Histoch Cytochem2004，39，： | 1 |
| 17 | 1' - acetoxychavicol acetate as an inhibitor of phagocytosis macrophages显示文摘 | Watababe N Kataka T Tajika T | 1995 | Biosci Biotechnol Biochem1995，59，： | 1 |
| 18 | Aquaporins : water channel proteins of the cell membrane 显示文摘 | Takata K Matsuzaki T Tajika Y | 2004 | Prog Histochem Cytochem2004，39，： | 1 |
| 19 | Risk factors for vitamin D deficiency in patients with Crohn’s disease显示文摘 | Masahiro Tajika Akira Matsuura Tsuneya Nakamura Takashi Suzuki Akira Sawaki Tetsuya Kato Kazuo Hara Kenji Ookubo Kenji Yamao Masahiko Kato Yasutoshi Muto | 2004 | Journal of Gastroenterology2004，，6： | 1 |
| 20 | 显示文摘 | Matsuzaki T Tajika Y Ablimit A | 2004 | Med Electron Microsc2004，37，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员